Rivastigmine
- Generic Name
- Rivastigmine
- Brand Names
- Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C14H22N2O2
- CAS Number
- 123441-03-2
- Unique Ingredient Identifier
- PKI06M3IW0
- Background
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
- Indication
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
- Associated Conditions
- Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease
Rivastigmine Study in Adolescents With Down Syndrome
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- Duke University
- Target Recruit Count
- 42
- Registration Number
- NCT01084135
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
Rivastigmine as a Treatment for Methamphetamine Dependence
- Conditions
- Methamphetamine DependenceSubstance AbuseMethamphetamine Abuse
- Interventions
- Other: Placebo
- First Posted Date
- 2010-02-23
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT01073319
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
- First Posted Date
- 2010-01-13
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 51
- Registration Number
- NCT01047579
- Locations
- 🇮🇱
Novartis Investigational Site, Haifa, Israel
🇮🇱Novartis Investigative Site, Tel Aviv, Israel
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
- Conditions
- Cocaine AddictionSubstance AbuseCocaine DependenceCocaine Abuse
- Interventions
- Drug: PlaceboDrug: Huperzine A 0.4 mgDrug: Huperzine A 0.8 mg
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 72
- Registration Number
- NCT01030692
- Locations
- 🇺🇸
Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States
Exelon Patch and Combination With Memantine Comparative Trial
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2010-05-19
- Lead Sponsor
- Inha University Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT01025466
- Locations
- 🇰🇷
The Catholic University of Korea Hospital, Bucheon, Korea, Republic of
🇰🇷Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷Donga University Hospital, Busan, Korea, Republic of
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
- Conditions
- Parkinsons Disease With Mild to Moderate Memory and/or Thinking ProblemsParkinsons Disease With Dementia
- Interventions
- First Posted Date
- 2009-10-01
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 15
- Registration Number
- NCT00988117
- Locations
- 🇺🇸
UCalifornia SF, San Francisco, California, United States
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 716
- Registration Number
- NCT00948766
- Locations
- 🇺🇸
University Neurology, Inc., Cincinnati, Ohio, United States
🇺🇸MidAmerica Neuroscience Reseach Institute, Lenexa, Kansas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
- Conditions
- Multiple SclerosisCognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT00881205
- Locations
- 🇩🇪
Novartis Investigational Site, Hamburg, Germany
🇩🇪Novartis Investigative Site, Wolfratshausen, Germany
🇩🇪Novartis Investigative SIte, Berlin, Germany
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
- Conditions
- Postoperative Cognitive DysfunctionDelirium
- Interventions
- Other: Placebo Patch
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 30
- Registration Number
- NCT00835159
- Locations
- 🇺🇸
NYU Langone Medical Center, Department of Anesthesiology 550 First Avenue, RR-603, New York, New York, United States
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
- Conditions
- Parkinson's DiseaseApathyno Dementia
- Interventions
- Drug: placebo
- First Posted Date
- 2008-10-06
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 40
- Registration Number
- NCT00767091
- Locations
- 🇫🇷
Devos, Lille, Nord, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.